Seeking Alpha

Sarepta Therapeutics (SRPT +8%) moves up on the back of on a positive article in Seeking Alpha...

Sarepta Therapeutics (SRPT +8%) moves up on the back of on a positive article in Seeking Alpha today, saying the stock looks "ridiculously overvalued" at current levels. Contributor Sean Anderson notes a number of potential catalysts to move the stock higher, but most significant is how little attention the stock currently gets on the Street, which could quickly change if of it's eteplirsen, a potential blockbuster treatment for Duchenne's disease, to receive early approval.
From other sites
Comments (4)
  • ari5000
    , contributor
    Comments (371) | Send Message
    does whoever wrote this knows what "overvalued" means?
    5 Nov 2012, 02:34 PM Reply Like
  • upster51
    , contributor
    Comments (7) | Send Message
    oops-- they meant 'ridcul;ously undervaluled' .. lol
    5 Nov 2012, 02:38 PM Reply Like
  • Asherp20
    , contributor
    Comments (15) | Send Message
    I think you meant to write undervalued.
    5 Nov 2012, 03:05 PM Reply Like
  • sstrand1
    , contributor
    Comments (240) | Send Message
    wow how does something that blatant get by review b 4 going out to the investment community? and then where is the author issuing an apology and correction??? helllooooo??
    6 Nov 2012, 09:17 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs